Project description:The dataset comprises array CGH data of 64 prostate cancer specimens performed on Stanford cDNA microarrays, to accompany the study of J Lapointe et al (2007). For each array, Channel 2 represents Cy5-labeled prostate genomic DNA, and Channel 1 Cy3-labeled normal male genomic DNA. Set of arrays organized by shared biological context, such as organism, tumors types, processes, etc. Keywords: Logical Set, array CGH
Project description:The dataset comprises array CGH data of 64 prostate cancer specimens performed on Stanford cDNA microarrays, to accompany the study of J Lapointe et al (2007). For each array, Channel 2 represents Cy5-labeled prostate genomic DNA, and Channel 1 Cy3-labeled normal male genomic DNA. Set of arrays organized by shared biological context, such as organism, tumors types, processes, etc. Using regression correlation
Project description:miRNA expression profiles were evaluated in a series of 64 prostate clinical specimens, including 32 cancer and 32 non-neoplastic tissues. For 26 individuals, paired cancer and non-neplastic tissue was available.
Project description:1,322 morphologically unidentified fragmentary bone specimens were analyzed using MALDI-TOF and a subset of 341 bone specimens with LC-MS/MS in order to characterize their proteome for species identification and potential hominin specimens related to the LRJ transitional period derived from the site Ilsenhöhle Ranis, Germany (50°39.7563’N, 11°33.9139’E).
Project description:miRNA expression profiles were evaluated in a series of 64 prostate clinical specimens, including 32 cancer and 32 non-neoplastic tissues. For 26 individuals, paired cancer and non-neplastic tissue was available. Tumor and non-neoplastic tissues were obtained, with appropriate informed consent and Institutional Review Board approval, from untreated prostate cancer patients subjected to radical prostatectomy. Freshly frozen surgical blocks were carefully dissected by the pathologist using H&E-stained sections as a template to identify areas containing at least 70% of tumor or normal cells. The total series comprises 64 clinical specimens, of which 32 from cancer areas and 32 from benign areas. For 26 patients, matched tumor and normal samples were available.
